Talk to Us

Regence BlueCross BlueShield of Oregon prior authorization, page 10

CPT code lookup

Each row is one code from the public prior authorization list. The description is the procedure or service name on that source row. This is not a coverage decision.

Prior authorization codes

Prior authorization codes
CodeDescriptionSource
81522Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast CancerCommercial Pre-authorization List, Pg 1 Original policy
81523Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast CancerCommercial Pre-authorization List, Pg 1 Original policy
S3854Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast CancerCommercial Pre-authorization List, Pg 1 Original policy
81258Diagnostic Genetic Testing for α-ThalassemiaCommercial Pre-authorization List, Pg 1 Original policy
81259Diagnostic Genetic Testing for α-ThalassemiaCommercial Pre-authorization List, Pg 1 Original policy
81269Diagnostic Genetic Testing for α-ThalassemiaCommercial Pre-authorization List, Pg 1 Original policy
0417UPrimary Mitochondrial DisordersCommercial Pre-authorization List, Pg 1 Original policy
81440Primary Mitochondrial DisordersCommercial Pre-authorization List, Pg 1 Original policy
81460Primary Mitochondrial DisordersCommercial Pre-authorization List, Pg 1 Original policy
81465Primary Mitochondrial DisordersCommercial Pre-authorization List, Pg 1 Original policy
S3870Chromosomal Microarray Analysis (CMA) or Copy Number Analysis for the Genetic Evaluation of Patients with Developmental Delay Intellectual Disability, Autism Spectrum Disorder or Congenital AnomaliesCommercial Pre-authorization List, Pg 1 Original policy
81450Myeloid Neoplasms and LeukemiaCommercial Pre-authorization List, Pg 1 Original policy
81451Myeloid Neoplasms and LeukemiaCommercial Pre-authorization List, Pg 1 Original policy
81455Myeloid Neoplasms and LeukemiaCommercial Pre-authorization List, Pg 1 Original policy
81456Myeloid Neoplasms and LeukemiaCommercial Pre-authorization List, Pg 1 Original policy
81412Evaluating the Utility of Genetic PanelsCommercial Pre-authorization List, Pg 1 Original policy
81434Evaluating the Utility of Genetic PanelsCommercial Pre-authorization List, Pg 1 Original policy
81437Evaluating the Utility of Genetic PanelsCommercial Pre-authorization List, Pg 1 Original policy
81443Evaluating the Utility of Genetic PanelsCommercial Pre-authorization List, Pg 1 Original policy
81448Diagnosis of Inherited Peripheral NeuropathiesCommercial Pre-authorization List, Pg 1 Original policy
81161Duchenne and Becker Muscular DystrophyCommercial Pre-authorization List, Pg 1 Original policy
0536UFetal Red Blood Cell Antigen Genotyping Using Maternal PlasmaCommercial Pre-authorization List, Pg 1 Original policy
0214UWhole Exome and Whole Genome SequencingCommercial Pre-authorization List, Pg 1 Original policy
0215UWhole Exome and Whole Genome SequencingCommercial Pre-authorization List, Pg 1 Original policy
0672UWhole Exome and Whole Genome SequencingCommercial Pre-authorization List, Pg 1 Original policy
0673UWhole Exome and Whole Genome SequencingCommercial Pre-authorization List, Pg 1 Original policy
81415Whole Exome and Whole Genome SequencingCommercial Pre-authorization List, Pg 1 Original policy
81416Whole Exome and Whole Genome SequencingCommercial Pre-authorization List, Pg 1 Original policy
81188Genetic Testing for EpilepsyCommercial Pre-authorization List, Pg 1 Original policy
81189Genetic Testing for EpilepsyCommercial Pre-authorization List, Pg 1 Original policy
81190Genetic Testing for EpilepsyCommercial Pre-authorization List, Pg 1 Original policy
0037UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0048UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0211UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0250UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0334UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0379UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0473UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0523UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0538UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0543UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0648UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0696UExpanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
81445Expanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
81449Expanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
81457Expanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
81458Expanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
81459Expanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
Q4223Expanded Molecular Panel Testing of Cancers to Select Targeted TherapiesCommercial Pre-authorization List, Pg 1 Original policy
0364UClonoSEQ® Testing for the Assessment of Measurable Residual Disease (MRD)Commercial Pre-authorization List, Pg 1 Original policy

Sources

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.

This website uses cookies to ensure you get the best experience on our website. Learn more